Is MYGN or NTLA more undervalued in 2026?

CirclFi compares Myriad Genetics, Inc. (MYGN) and Intellia Therapeutics, Inc. (NTLA) using 13 institutional-grade valuation models. MYGN has a Quality of Company score of 6.6/10 while NTLA scores 6.5/10.

Which is a better buy — MYGN or NTLA?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do MYGN and NTLA valuations compare?

MYGN at $3.97 and NTLA at $14.07 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

MYGN vs NTLA Valuation Comparison 2026 — Intrinsic Value Analysis

MYGN

In Vitro & In Vivo Diagnostic Substances

Myriad Genetics, Inc.

Quality

6.6

out of 10

Value Trap

SAFE

Price

$3.97

Last close

Models

12/13

Active

NTLA

In Vitro & In Vivo Diagnostic Substances

Intellia Therapeutics, Inc.

Quality

6.5

out of 10

Value Trap

SAFE

Price

$14.07

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	MYGN Fair Value	MYGN Upside	NTLA Fair Value	NTLA Upside
Bayesian DCF	Intrinsic	$0.08	-98.1%	$3.57	-74.7%
Earnings Power Value	Intrinsic	$16.62	+318.7%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$3.09	-22.1%	$0.55	-95.5%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for MYGN vs NTLA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

MYGN vs NTLA — Which Stock Is More Undervalued?

MYGN scores higher with a 6.6/10 quality rating vs NTLA's 6.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Myriad Genetics, Inc. (MYGN) and Intellia Therapeutics, Inc. (NTLA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

MYGN currently trades at $3.97 with a QOC of 6.6/10, while NTLA trades at $14.07 with a QOC of 6.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).